ADRMF (Adherium) ROC (Joel Greenblatt) %: -10,834.29% (As of Dec. 2025)


What is Adherium ROC (Joel Greenblatt) %?

Adherium ADRMF ROC (Joel Greenblatt) % is -10,834.29% as of Dec. 2025. The stock has 8 warning signs investors should review. Among 841 Medical Devices & Instruments companies, Adherium ranks worse than 95.24% on this metric.

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Adherium's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -10,834.29%.

The historical rank and industry rank for Adherium's ROC (Joel Greenblatt) % or its related term are showing as below:

ADRMF' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -7233.22   Med: -5241.9   Max: 600.5
Current: -1741.89

During the past 10 years, Adherium's highest ROC (Joel Greenblatt) % was 600.50%. The lowest was -7233.22%. And the median was -5241.90%.

ADRMF's ROC (Joel Greenblatt) % is ranked worse than
95.24% of 841 companies
in the Medical Devices & Instruments industry
Industry Median: 4.13 vs ADRMF: -1741.89

Adherium's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.


Adherium  (OTCPK:ADRMF) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


Adherium ROC (Joel Greenblatt) % Related Terms


Adherium ROC (Joel Greenblatt) % Historical Data

* Premium members only.

The historical data trend for Adherium's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Adherium ROC (Joel Greenblatt) % Chart

Adherium Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
ROC (Joel Greenblatt) %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -7,556.76 -4,976.03 -3,971.17 0.00 0.00

Adherium Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1,268.99 -5,267.74 -4,121.43 -1,291.10 -10,834.29

ADRMF vs ABT, SYK, MDT: ROC (Joel Greenblatt) % Comparison

For the Medical Devices subindustry, Adherium's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Adherium ROC (Joel Greenblatt) % vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Adherium's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Adherium's ROC (Joel Greenblatt) % falls into.



Adherium ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Jun. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.053 + 1.197 + 0.287) - (2.01 + 0.536 + 0.794)
=-1.803

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.936 + 1.068 + 0.266) - (1.499 + 0 + 0.891)
=-0.12

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of Adherium for the quarter that ended in Dec. 2025 can be restated as:

ROC (Joel Greenblatt) %(Q: Dec. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2025  Q: Dec. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-7.584/( ( (0.075 + max(-1.803, 0)) + (0.065 + max(-0.12, 0)) )/ 2 )
=-7.584/( ( 0.075 + 0.065 )/ 2 )
=-7.584/0.07
=-10,834.29 %

Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROC (Joel Greenblatt) % of -10,834.29% mean?
Adherium (ADRMF) has a ROC (Joel Greenblatt) % of -10,834.29% as of Dec. 2025. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Adherium and its competitors. According to the industry distribution chart, Adherium ranks #801 out of 841 companies in the Medical Devices & Instruments industry, placing it in the top 95.2%.
Is Adherium's ROC (Joel Greenblatt) % too high?
Adherium's current ROC (Joel Greenblatt) % is -10,834.29%. Based on the distribution chart, Adherium ranks #801 out of 841 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers.
How does Adherium's ROC (Joel Greenblatt) % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Adherium ranks #801 out of 841 companies for ROC (Joel Greenblatt) %. This places Adherium in the lower half of its industry. The industry median ROC (Joel Greenblatt) % is 4.13. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Medical Devices & Instruments company?
The median ROC (Joel Greenblatt) % among Medical Devices & Instruments companies is 4.13, based on 841 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Adherium and its competitors. For the Medical Devices & Instruments industry, the median ROC (Joel Greenblatt) % is 4.13 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Adherium's current ROC (Joel Greenblatt) % is -10,834.29%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adherium stock overvalued right now?
Based on GuruFocus' analysis, Adherium (ADRMF) is currently considered Possible Value Trap. The current ROC (Joel Greenblatt) % is -10,834.29%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Adherium (ADRMF), the current ROC (Joel Greenblatt) % is -10,834.29% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Adherium Business Description

Other Exchanges ADR:Australia
Address 447 Collins Street, Level 5, Melbourne, VIC, AUS, 3000
Adherium Ltd is engaged in the development, manufacture, and supply of its Hailie digital health technologies that address sub-optimal medication use and improve health outcomes in chronic disease. It is an international Respiratory eHealth company focused on patient medication adherence, remote monitoring, and data management solutions for patients, payers, and providers. Its geographically segments include New Zealand and Australia, Europe, North America, and Asia. The majority of its revenue comes from Europe.